



# **Neovasc Inc.**

## **UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE THREE AND NINE MONTHS ENDED  
SEPTEMBER 30, 2022 AND 2021**

**(Expressed in U.S. dollars)**

## CONTENTS

	<u>Page</u>
Unaudited Condensed Interim Consolidated Statements of Financial Position	1
Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss	2
Unaudited Condensed Interim Consolidated Statements of Changes in Equity	3
Unaudited Condensed Interim Consolidated Statements of Cash Flows	4
Notes to the Unaudited Condensed Interim Consolidated Financial Statements	5 – 34

# NEOVASC INC.

## Unaudited Condensed Interim Consolidated Statements of Financial Position (Expressed in U.S. dollars)

	Notes	September 30, 2022	December 31, 2021
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	6	\$ 31,254,368	\$ 51,537,367
Accounts receivable	7	1,689,596	1,369,455
Finance lease receivable	8	-	43,543
Inventory	9	1,285,263	1,480,077
Prepaid expenses and other assets	10	368,766	787,734
<b>Total current assets</b>		<b>34,597,993</b>	<b>55,218,176</b>
<b>Non-current assets</b>			
Restricted cash	11	436,498	469,808
Right-of-use asset	12	333,708	456,339
Property and equipment	13	181,219	182,041
Deferred loss on 2020 derivative warrant liabilities	16	1,598,357	4,300,484
Deferred loss on 2021 derivative warrant liabilities	16	7,428,944	9,898,475
<b>Total non-current assets</b>		<b>9,978,726</b>	<b>15,307,147</b>
<b>Total assets</b>		<b>\$ 44,576,719</b>	<b>\$ 70,525,323</b>
<b>LIABILITIES AND EQUITY</b>			
<b>Liabilities</b>			
<b>Current liabilities</b>			
Accounts payable and accrued liabilities	14	\$ 3,739,429	\$ 4,629,163
Lease liabilities	15	224,195	273,145
2019 Convertible notes	16	-	38,633
2020 Convertible notes	16	-	40,587
2022 Convertible notes		135,863	-
<b>Total current liabilities</b>		<b>4,099,487</b>	<b>4,981,528</b>
<b>Non-Current Liabilities</b>			
Lease liabilities	15	200,725	272,652
2019 Convertible notes	16	-	6,548,796
2020 Convertible notes, warrants and derivative warrant liabilities	16	126,355	6,088,728
2021 Derivative warrant liabilities	16	57,609	405,508
2022 Convertible notes	16	12,029,305	-
<b>Total non-current liabilities</b>		<b>12,413,994</b>	<b>13,315,684</b>
<b>Total liabilities</b>		<b>\$ 16,513,481</b>	<b>\$ 18,297,212</b>
<b>Equity</b>			
Share capital	17	\$ 441,153,987	\$ 439,873,457
Contributed surplus	17	42,491,190	40,355,952
Accumulated other comprehensive loss		(6,229,804)	(7,885,024)
Deficit		(449,352,135)	(420,116,274)
<b>Total equity</b>		<b>28,063,238</b>	<b>52,228,111</b>
<b>Total liabilities and equity</b>		<b>\$ 44,576,719</b>	<b>\$ 70,525,323</b>

Going Concern and Uncertainty (see Note 1(b) and 5(d))  
Contingent Liabilities and Provisions (see Note 23)

## NEOVASC INC.

### Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

	Notes	For the Three Months Ended September 30		For the Nine Months Ended September 30	
		2022	2021	2022	2021
<b>REVENUE</b>	18	\$ 923,311	\$ 703,420	\$ 2,352,118	\$ 1,788,282
<b>COST OF GOODS SOLD</b>		<b>220,030</b>	164,843	<b>514,249</b>	346,342
<b>GROSS PROFIT</b>		<b>703,281</b>	538,577	<b>1,837,869</b>	1,441,940
<b>EXPENSES</b>					
Selling expenses	20	1,062,454	786,366	3,276,625	2,257,157
General and administrative expenses	20	2,336,874	2,999,003	8,477,598	13,334,376
Product development and clinical trials expenses	20	4,044,443	3,477,884	11,655,659	11,840,199
		<b>7,443,771</b>	7,263,253	<b>23,409,882</b>	27,431,732
<b>OPERATING LOSS</b>		<b>(6,740,490)</b>	(6,724,676)	<b>(21,572,013)</b>	(25,989,792)
<b>OTHER (EXPENSE)/INCOME</b>					
Interest and other income		105,412	507,775	175,030	557,529
Interest and other expense		(427,207)	(33,551)	(1,166,472)	(352,114)
Loss on foreign exchange		(106,316)	(8,162)	(116,124)	(28,400)
Unrealized (loss)/gain on warrants, derivative liability	16	(28,624)	1,738,258	433,014	16,997,651
warrants and convertible notes					
Realized loss on exercise or conversion and extinguishment of warrants, derivative liability	16	-	(223,747)	(1,845,822)	(2,119,091)
warrants and convertible notes					
Amortization of deferred loss		(1,029,470)	(2,791,494)	(3,271,316)	(7,817,937)
		<b>(1,486,205)</b>	(810,921)	<b>(5,791,690)</b>	7,237,638
<b>LOSS BEFORE TAX</b>		<b>(8,226,695)</b>	(7,535,597)	<b>(27,363,703)</b>	(18,752,154)
Tax recovery		-	-	-	16,128
<b>LOSS FOR THE PERIOD</b>		<b>\$ (8,226,695)</b>	\$ (7,535,597)	<b>\$ (27,363,703)</b>	\$ (18,736,026)
<b>OTHER COMPREHENSIVE LOSS FOR THE PERIOD</b>					
Fair market value changes in convertible notes due to changes in own credit risk		-	619,635	(216,938)	(366,002)
<b>LOSS AND OTHER COMPREHENSIVE LOSS FOR THE PERIOD</b>		<b>\$ (8,226,695)</b>	\$ (6,915,962)	<b>\$ (27,580,641)</b>	\$ (19,102,028)
<b>LOSS PER SHARE</b>					
Basic and diluted loss per share	21	\$ (3.00)	\$ (2.79)	\$ (10.03)	\$ (7.63)

See Accompanying Notes to the Unaudited Condensed Interim Consolidated Financial Statements

# NEOVASC INC.

## Unaudited Condensed Interim Consolidated Statements of Changes in Equity

(Expressed in U.S. dollars)

	Notes	Share Capital	Contributed Surplus	Accumulated Other Comprehensive Loss	Deficit	Total Equity
<b>Balance at January 1, 2021</b>		<b>\$ 369,775,383</b>	<b>\$ 35,045,056</b>	<b>\$ (7,615,717)</b>	<b>\$ (395,227,205)</b>	<b>\$ 1,977,517</b>
Issue of share capital on public offering (net of share issuance costs)	17(a)	66,868,911	-	-	-	66,868,911
Issue of share capital on exercise of warrants	17(a)	3,704,828	-	-	-	3,704,828
Issue of share capital on vesting of restricted stock units	17(a)	1,235,197	(1,235,197)	-	-	-
Issue of compensation warrants	17(a)	(1,898,959)	1,898,959	-	-	-
Share-based payments	20	-	4,152,157	-	-	4,152,157
<b>Transactions with owners during the period</b>		<b>69,909,977</b>	<b>4,815,919</b>	<b>-</b>	<b>-</b>	<b>74,725,896</b>
Loss for the period		-	-	-	(18,736,026)	(18,736,026)
Other comprehensive loss for the period		-	-	(366,002)	-	(366,002)
<b>Balance at September 30, 2021</b>		<b>\$ 439,685,360</b>	<b>\$ 39,860,975</b>	<b>\$ (7,981,719)</b>	<b>\$ (413,963,231)</b>	<b>\$ 57,601,385</b>
<b>Balance at January 1, 2022</b>		<b>\$ 439,873,457</b>	<b>\$ 40,355,952</b>	<b>\$ (7,885,024)</b>	<b>\$ (420,116,274)</b>	<b>\$ 52,228,111</b>
Issue of convertible notes	16(c)	-	974,136	-	-	974,136
Issue of share capital on vesting of restricted stock units	17(a)	1,276,863	(1,276,863)	-	-	-
Issue of share capital on exercise of stock options	17(a)	3,667	(1,478)	-	-	2,189
Share-based payments	20	-	2,439,443	-	-	2,439,443
<b>Transactions with owners during the period</b>		<b>1,280,530</b>	<b>2,135,238</b>	<b>-</b>	<b>-</b>	<b>3,415,768</b>
Loss for the period		-	-	-	(27,363,703)	(27,363,703)
Other comprehensive loss for the period		-	-	(216,938)	-	(216,938)
Transfer of credit risk reserve upon extinguishment of convertible notes	16(c)	-	-	1,872,158	(1,872,158)	-
<b>Balance at September 30, 2022</b>		<b>\$ 441,153,987</b>	<b>\$ 42,491,190</b>	<b>\$ (6,229,804)</b>	<b>\$ (449,352,135)</b>	<b>\$ 28,063,238</b>

See Accompanying Notes to the Unaudited Condensed Interim Consolidated Financial Statements

# NEOVASC INC.

## Unaudited Condensed Interim Consolidated Statements of Cash Flows

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

	Notes	For the Three Months Ended September 30		For the Nine Months Ended September 30	
		2022	2021	2022	2021
<b>OPERATING ACTIVITIES</b>					
Loss for the period		\$ (8,226,695)	\$ (7,535,597)	\$ (27,363,703)	\$ (18,736,026)
Adjustments for:					
Depreciation	20	86,311	145,088	310,407	524,388
Share-based payments	20	921,600	1,783,675	2,579,930	6,234,751
Accretion on collaboration, license and settlement agreement provision		-	12,931	-	63,400
Unrealized loss/(gain) on warrants, derivative liability warrants and convertible notes	16	28,624	(1,738,258)	(433,014)	(16,997,651)
Realized loss on exercise or conversion of warrants, derivative liability warrants and convertible notes	16	-	223,747	1,845,822	2,119,091
Amortization of deferred loss		1,029,470	2,791,494	3,271,316	7,817,936
Legal expenses and underwriters fees from financing activity		-	-	(147,814)	1,546,811
Gain on disposal of assets		-	-	-	(1,849)
Write down of fixed assets for obsolescence		-	-	-	593,622
Income tax recovery		-	-	-	(16,128)
Interest expense		321,795	10,695	991,442	281,354
		<u>(5,838,895)</u>	<u>(4,306,225)</u>	<u>(18,945,614)</u>	<u>(16,570,301)</u>
Net change in non-cash working capital items:					
Accounts receivable		(6,419)	(580,012)	(276,863)	(818,874)
Inventory		(19,432)	(214,097)	194,814	(762,343)
Research and development supplies		-	(9,082)	-	146,444
Prepaid expenses and other assets		(18,401)	63,490	418,968	(201,774)
Accounts payable and accrued liabilities		(483,468)	(1,073,169)	(1,040,111)	(3,327,009)
Payment of amounts due on collaboration, license and settlement agreements		-	(1,250,000)	-	(1,250,000)
		<u>(527,720)</u>	<u>(3,062,870)</u>	<u>(703,192)</u>	<u>(6,213,556)</u>
Income tax and Interest paid and received:					
Income tax recovery		-	-	-	16,128
Interest received		68,122	11,507	108,019	40,668
		<u>68,122</u>	<u>11,507</u>	<u>108,019</u>	<u>56,796</u>
<b>Net cash applied to operating activities</b>		<b><u>(6,298,493)</u></b>	<b><u>(7,357,588)</u></b>	<b><u>(19,540,787)</u></b>	<b><u>(22,727,061)</u></b>
<b>INVESTING ACTIVITIES</b>					
Purchase of property, plant and equipment	13	(4,142)	-	(52,467)	(146,058)
<b>Net cash applied to investing activities</b>		<b><u>(4,142)</u></b>	<b><u>-</u></b>	<b><u>(52,467)</u></b>	<b><u>(146,058)</u></b>
<b>FINANCING ACTIVITIES</b>					
Proceeds from public offering net of share issuance costs	17(a)	-	-	-	65,322,100
Proceeds from exercise of warrants	17(a)	-	-	-	1,078,623
Proceeds from exercise of stock options		2,190	-	2,190	-
Payment of interest on convertible note		-	-	(432,300)	(255,371)
Payment of lease obligation		(76,921)	(110,264)	(259,635)	(381,067)
<b>Net cash (applied to)/from financing activities</b>		<b><u>(74,731)</u></b>	<b><u>(110,264)</u></b>	<b><u>(689,745)</u></b>	<b><u>65,764,285</u></b>
<b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>		<b><u>(6,377,366)</u></b>	<b><u>(7,467,852)</u></b>	<b><u>(20,282,999)</u></b>	<b><u>42,891,166</u></b>
Beginning of the period		37,631,734	63,294,878	51,537,367	12,935,860
End of the period		<u>\$ 31,254,368</u>	<u>\$ 55,827,026</u>	<u>\$ 31,254,368</u>	<u>\$ 55,827,026</u>

See Accompanying Notes to the Unaudited Condensed Interim Consolidated Financial Statements

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 1. INCORPORATION AND GOING CONCERN

#### (a) Business description

Neovasc Inc. (“Neovasc” or the “Company”) is a company incorporated and domiciled in Canada. The Company was incorporated as Medical Ventures Corp. under the Company Act (British Columbia) on November 2, 2000, and was continued under the Canada Business Corporations Act on April 19, 2002. On July 1, 2008, the Company changed its name to Neovasc Inc. Neovasc is the parent company.

The unaudited condensed interim consolidated financial statements of the Company as at September 30, 2022 and for the three and nine months ended September 30, 2022 and 2021 comprise the Company and its subsidiaries, all of which are wholly owned. The Company’s principal place of business is located at 2135 – 13700 Mayfield Place, Richmond, British Columbia, V6V 2E4, Canada and the Company’s registered office is located at Suite 2600 – 595 Burrard Street, Vancouver, British Columbia, V7X 1L3, Canada. The Company’s shares are listed on the Toronto Stock Exchange (TSX: NVCN) and the Nasdaq Capital Market (NASDAQ: NVCN).

Neovasc is a specialty medical device company that develops and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ (“Reducer”), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™ (“Tiara”), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe.

#### (b) Going concern and uncertainty

As at September 30, 2022, the Company had approximately \$31.2 million in cash and cash equivalents being sufficient cash on hand to extend the operations of the Company until the first quarter of 2024 at the current anticipated burn rate. However, given the FDA’s decision to approve the Investigational Device Exemption (“IDE”) for the COSIRA-II clinical study, and the growing body of evidence supporting development of new patient groups, it is possible that the Company will initiate programs that will require additional significant expenditures and that the increasing cash needs of the Company could shorten the time the proceeds will meet the requirements of the Company. In addition, COVID-19 has impacted the Company’s ability to generate revenue, enroll patients in clinical studies, complete certain Tiara TA bench testing milestones on its expected schedule, and raise capital. The Company can give no assurance that it will be able to obtain the additional funds needed in the future, on terms agreeable to the Company, or at all. These circumstances indicate the existence of material uncertainty and cast substantial doubt about the Company’s ability to continue as a going concern.

The Company will re-evaluate the going concern risk at each reporting period and will consider removing the going concern and uncertainty note if, and when, the Company can depend on the profitable commercialization of its products or is confident of obtaining additional debt, equity or other financing to fund ongoing operations until profitability is achieved.

These unaudited condensed interim consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumptions were not appropriate. Should the Company be unable to obtain additional capital in the future and the Company’s ability to continue as a going concern be impaired, material adjustments may be necessary to these unaudited condensed interim consolidated financial statements.

#### (c) Corporate reorganization

On June 20, 2021, the Company announced that it had indefinitely paused all product development activities on the Tiara TF device. Concurrent with this decision the Company terminated 40% of its staff and took a provision for obsolete leasehold improvements and equipment related to these activities.

On September 20, 2022, the Company announced that it had indefinitely paused all product development on the Tiara TA device. There were no staff terminated and no material write downs related to this decision.

#### (d) Share consolidation (reverse stock split)

On April 29, 2022, the Company effected a share consolidation (reverse stock split) of its issued and outstanding Common Shares on the basis of one post-consolidation Common Share for every 25 pre-consolidation Common Shares. All references in these consolidated financial statements to Common Shares and options have been retroactively adjusted to reflect the share consolidation.

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 1. INCORPORATION AND GOING CONCERN (continued)

#### (e) Nasdaq listing

On December 10, 2020, the Company received written notification from the Nasdaq Listing Qualifications Department notifying the Company that it was not in compliance with the \$35 million minimum market value requirement set forth in the Nasdaq Marketplace Rules. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until June 8, 2021, to regain compliance. On February 25, 2021, the Company announced that it had received written notification from the Nasdaq notifying the Company that it had regained compliance with the minimum market value requirement under Nasdaq Listing Rule 5550(b)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.

On December 14, 2020, the Company received written notification from the Nasdaq Listing Qualifications Department notifying the Company that it was not in compliance with the \$1.00 minimum bid price requirement set forth in the Nasdaq Marketplace Rules. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until June 14, 2021, to regain compliance. On February 9, 2021, the Company announced that it had received written notification from the Nasdaq notifying the Company that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.

On May 25, 2021, the Company received written notification from the Nasdaq Listing Qualifications Department notifying the Company that it was not in compliance with the \$1.00 minimum bid price requirement set forth in the Nasdaq Marketplace Rules. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until November 22, 2021, to regain compliance. In accordance with Nasdaq Listing Rule 5810(c)(3)(A)(i), the Company requested and was granted a second 180-calendar day period, or until May 23, 2022, within which to evidence compliance with the \$1.00 bid price requirement. On May 16, 2022, the Company announced that it has received written notification from the Nasdaq informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.

#### (f) Impacts of COVID-19 pandemic

The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is difficult to predict, as the response to the pandemic evolves on a country-by-country basis. Furthermore, capital markets and economies worldwide have also been disrupted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global adverse economic events. Such economic disruption could have a material adverse effect on the Company's business.

The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company's customers, all of which are uncertain and cannot be predicted. As at September 30, 2022, the Company has seen a marked impact on Reducer revenues due to restrictions on elective procedures which included Reducer implants. Furthermore, the Company's recruitment to clinical trials and studies continues to be enrolling slower than expected due to the pandemic restrictions.

The Company's future results of operations and liquidity could be adversely impacted by a decrease in Reducer sales, delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. As of the date of issuance of these condensed interim consolidated financial statements, the extent to which the COVID-19 pandemic may further materially impact the Company's financial condition, liquidity, or results of operations is uncertain.



# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 2. BASIS OF PREPARATION

#### (a) Statement of compliance with IFRS

These unaudited condensed interim consolidated financial statements are prepared in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB"), using the accounting policies consistent with the Company's audited annual consolidated financial statements for the years ended December 31, 2021, 2020 and 2019, and as well as the instructions and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") for interim reporting. These unaudited condensed interim consolidated financial statements and accompanying notes should be read in conjunction with the Company's audited annual consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 20-F for the years ended December 31, 2021, 2020 and 2019 and the accompanying notes included in those financial statements which was filed with the SEC on March 10, 2022. For a full description of accounting policies, refer to the audited annual consolidated financial statements of the Company for the years ended December 31, 2021, 2020 and 2019.

The results for the three and nine months ended September 30, 2022 may not be indicative of the results that may be expected for the full year or any other period.

#### (b) Basis of consolidation

These unaudited condensed interim consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd. (which is in the process of being voluntarily liquidated), Neovasc GmbH, Neovasc (UK) Ltd., and Neovasc Management Inc. All intercompany balances and transactions have been eliminated upon consolidation.

#### (c) Presentation of financial statements

The Company has elected to present the 'Statements of Loss and Comprehensive Loss' in a single statement.

### 3. SIGNIFICANT ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited annual consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 20-F for the years ended December 31, 2021, 2020 and 2019 and the accompanying notes included in those financial statement, most notably Note 2.

### 4. MANAGING CAPITAL

The Company's objectives, when managing capital, are to safeguard cash as well as maintain financial liquidity and flexibility in order to preserve its ability to meet financial obligations and deploy capital to grow its business. In the definition of capital, the Company includes equity and the convertible notes. There has been no change in the definition since the prior year.

The Company's financial strategy is designed to maintain a flexible capital structure consistent with the objectives stated above and to respond to business growth opportunities and changes in economic conditions. In order to maintain or adjust its capital structure, the Company may issue new shares, new units or new debt (secured, unsecured, convertible and/or other types of available debt instruments). For the three and nine months ended September 30, 2022, there were no changes in the Company's capital management policy.

The capital of the Company is comprised of:

	<b>September 30, 2022</b>	December 31, 2021
2019 Convertible notes	\$ -	\$ 6,587,429
2020 Convertible notes	-	5,577,136
2020 Warrants and derivative warrant liabilities	<b>126,355</b>	552,179
2021 Derivative warrant liabilities	<b>57,609</b>	405,508
2022 Convertible notes	<b>12,165,168</b>	-
Equity	<b>28,063,238</b>	52,228,111
Capital	<b>\$ 40,412,370</b>	\$ 65,350,363

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 5. FINANCIAL RISK MANAGEMENT

#### (a) Fair value estimation

The fair value hierarchy establishes three levels to classify fair value measurements based upon the observability of significant inputs used in the valuation techniques. The three levels of the fair value hierarchy are described below:

Level 1 | Quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 | Inputs other than quoted prices included in level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices)

Level 3 | Inputs for the assets or liability that are not based on observable market data (that is, unobservable inputs)

The following table sets forth the Company's financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as at September 30, 2022 and December 31, 2021. As required by IFRS 13 - Fair Value Measurement, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

Presentation of the fair values of the 2020 Convertible notes, warrants and derivative warrant liabilities and 2021 Derivative warrant liabilities are gross of the deferred loss. The deferred loss on the 2020 Convertible notes, warrants and derivative warrant liabilities as at September 30, 2022 is \$1,598,357 (December 31, 2021: \$4,300,484). The deferred loss on the 2021 Derivative warrant liabilities as at September 30, 2022 is \$7,428,944 (December 31, 2021: \$9,898,475).

As at September 30, 2022:	Level 1	Level 2	Level 3	Total
<b>Financial liabilities at fair value through profit and loss</b>				
2020 Warrants and derivative warrant liabilities	\$ -	\$ -	\$ 126,355	\$ 126,355
2021 Derivative warrant liabilities	\$ -	\$ -	\$ 57,609	\$ 57,609

  

As at December 31, 2021:	Level 1	Level 2	Level 3	Total
<b>Financial liabilities at fair value through profit and loss</b>				
2019 Convertible notes	\$ -	\$ -	\$ 6,587,429	\$ 6,587,429
2020 Convertible notes, warrants and derivative warrant liabilities	\$ -	\$ -	\$ 6,129,315	\$ 6,129,315
2021 Derivative warrant liabilities	\$ -	\$ -	\$ 405,508	\$ 405,508

The carrying amounts of financial assets and financial liabilities in each category are as follows:

	Note	September 30, 2022	December 31, 2021
<b>Assets at amortized cost</b>			
Cash and cash equivalents	6	\$ 31,254,368	\$ 51,537,367
Accounts receivable	7	1,689,596	1,369,455
Restricted cash	11	436,498	469,808
		<b>\$ 33,380,462</b>	<b>\$ 53,376,630</b>
<b>Financial liabilities at amortized cost</b>			
Accounts payable and accrued liabilities	14	\$ 3,739,429	\$ 4,629,163
2022 Convertible notes	16(c)	12,165,168	-
<b>Financial liabilities at fair value through profit and loss</b>			
2019 Convertible notes	16(a)	-	6,587,429
2020 Convertible notes	16(b)	-	5,577,136
2020 Warrants and derivative warrant liabilities	16(d)	126,355	552,179
2021 Derivative warrant liabilities	16(d)	57,609	405,508
		<b>\$ 16,088,561</b>	<b>\$ 17,751,415</b>

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 5. FINANCIAL RISK MANAGEMENT (continued)

#### (a) Fair value estimation (continued)

The carrying amounts of cash and cash equivalents, accounts receivable, restricted cash and accounts payable and accrued liabilities are considered a reasonable approximation of fair value due to their short-term nature. The estimated fair value of the 2022 Convertible notes as at September 30, 2022 is \$10,887,448.

#### (b) Foreign exchange risk

A portion of the Company's revenues are derived from product sales in Europe and the United Kingdom, denominated in Euros and British Pounds, respectively. Management has considered the stability of the foreign currency and the impact a change in the exchange rate may have on future earnings during the forecasting process.

The Euro represents approximately 39% of revenues for the nine months ended September 30, 2022, (nine months ended September 30, 2021: 47%). A 10% change in the foreign exchange rates for the Euro for foreign currency-denominated accounts receivable will impact net income for the nine months ended September 30, 2022 by approximately \$34,550 (nine months ended September 30, 2021: \$14,113). The British Pound represents approximately 10% of revenues for the nine months ended September 30, 2022, (nine months ended September 30, 2021: nil%). A 10% change in the foreign exchange rates for the British Pound for foreign currency-denominated accounts receivable will impact net income for the nine months ended September 30, 2022 by approximately \$22,882 (nine months ended September 30, 2021: \$nil).

A similar change in foreign currency-denominated accounts payable, which are denominated in Canadian dollars and Euros will impact net income by approximately \$7,829 and \$29,604 respectively, for the nine months ended September 30, 2022 (nine months ended September 30, 2021: \$27,858 and \$68,951, respectively). A similar change in foreign currency-denominated cash and cash equivalents, and restricted cash, which are denominated in Canadian dollars and Euros will impact net income by approximately \$128,689 and \$75,345, respectively, for the nine months ended September 30, 2022 (nine months ended September 30, 2021: \$152,604 and \$70,983, respectively). The Company does not hedge its foreign exchange risk.

#### (c) Interest rate risk

The Company is not exposed to material cash flow interest rate risk on fixed-rate cash balances and short-term accounts receivable, accounts payable and the 2019, 2020 and 2022 Convertible notes that have fixed interest terms.

#### (d) Liquidity risk

As at September 30, 2022, the Company had \$31,254,368 in cash and cash equivalents as compared to cash and cash equivalents of \$51,537,367 as at December 31, 2021. The Company monitors its cash flow on a monthly basis and compares actual performance to the budget for the period. The Company may obtain additional debt or equity financing in future periods. Further into the future the Company is dependent on the profitable commercialization of its products or obtaining additional debt or equity financing to fund ongoing operations until profitability is achieved.

On February 12, 2021, the Company received aggregate gross proceeds of \$72 million from the February 2021 Financing (see Note 17). The proceeds from the February 2021 Financing and cash inflows from revenue generating activities could be sufficient to extend the operations of the Company until the first quarter of 2024 at the current anticipated burn rate. However, it is possible that the Company will initiate programs that were on hold given past cash constraints or to explore additional indications for its products and that the cash needs of the Company will increase, shortening the time the proceeds will meet the requirements of the Company.

Trade payables were aged as follows as at September 30, 2022 and do not include accrued liabilities. All trade payables are current liabilities:

	<b>Total</b>
Current	<b>\$ 673,578</b>
31-60 days	<b>107,154</b>
Over 60 days	<b>11,063</b>
	<b>\$ 791,795</b>

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 5. FINANCIAL RISK MANAGEMENT (continued)

#### (e) Credit risk

Credit risk arises from the possibility that the entities to which the Company sells products may experience financial difficulty and be unable to fulfill their contractual obligations. This risk is mitigated by proactive credit management policies that include regular monitoring of the debtor's payment history and performance. The Company does not require collateral from its customers as security for trade accounts receivable but may require certain customers to pay in advance of any work being performed or product being shipped.

The maximum exposure, if all the Company's customers were to default at the same time is the full carrying value of the trade accounts receivable. As at September 30, 2022, the trade accounts receivable are \$1,046,057 (as at December 31, 2021: \$720,332). As at September 30, 2022, the Company had \$395,560 (as at December 31, 2021: \$153,673) of trade accounts receivable that were overdue according to the customers' credit terms. All of the Company's trade and other receivables have been reviewed for impairment. During the three and nine months ended September 30, 2022, the Company wrote down \$nil of accounts receivable owed by customers (three and nine months ended September 30, 2021: \$nil).

The Company may also have credit risk related to its cash and cash equivalents and restricted cash, with a maximum exposure of \$31,690,866 as at September 30, 2022 (as at December 31, 2021: \$52,007,175). The Company minimizes its risk to cash and cash equivalents and restricted cash by maintaining the majority of its balances with Canadian Chartered Banks.

### 6. CASH AND CASH EQUIVALENTS

	September 30, 2022	December 31, 2021
Cash held in:		
United States dollars	\$ 29,650,529	\$ 49,745,012
Canadian dollars	850,391	963,340
Euros	753,448	829,015
	<u>\$ 31,254,368</u>	<u>\$ 51,537,367</u>

### 7. ACCOUNTS RECEIVABLE

	September 30, 2022	December 31, 2021
Trade accounts receivable	\$ 1,046,057	\$ 720,332
Other accounts receivable	110,457	111,605
Income tax receivable	533,082	537,518
	<u>\$ 1,689,596</u>	<u>\$ 1,369,455</u>

### 8. FINANCE LEASE RECEIVABLE

The Company entered into a sublease agreement which has been recognized as a finance lease. Finance lease receivables are presented in the statement of financial position as follows:

	September 30, 2022	December 31, 2021
Current and Total	<u>\$ -</u>	<u>\$ 43,543</u>

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 9. INVENTORY

	September 30, 2022	December 31, 2021
Raw materials	\$ 1,114,583	\$ 1,381,021
Work in progress	-	23,855
Finished goods	170,680	75,201
	<u>\$ 1,285,263</u>	<u>\$ 1,480,077</u>

During the three and nine months ended September 30, 2022, \$220,030 and \$514,249 of inventory was expensed in cost of goods sold (three and nine months ended September 30, 2021: \$164,843 and \$346,342).

### 10. PREPAID EXPENSES AND OTHER ASSETS

	September 30, 2022	December 31, 2021
Prepaid insurance	\$ 163,642	\$ 537,022
Deposits on rental agreements	68,060	103,688
Retainers for professional services	23,000	32,491
Other prepaid expenses and other assets	114,064	114,533
	<u>\$ 368,766</u>	<u>\$ 787,734</u>

### 11. RESTRICTED CASH

	September 30, 2022	December 31, 2021
Restricted cash	\$ 436,498	\$ 469,808

Restricted cash represents CAD \$600,000 security held by a Canadian Chartered Bank as a guarantee for the Company's same-day electronic processing facility and corporate credit card facility.

### 12. RIGHT OF USE ASSET

	Total
<b>COST</b>	
Balance as at January 1, 2021 and December 31, 2021	\$ 1,535,614
Lease modification	89,932
<b>Balance as at September 30, 2022</b>	<u>\$ 1,625,546</u>
<b>ACCUMULATED DEPRECIATION</b>	
Balance as at January 1, 2021	\$ 705,063
Depreciation for the year	374,212
Balance as at December 31, 2021	\$ 1,079,275
Depreciation for the period	212,563
<b>Balance as at September 30, 2022</b>	<u>\$ 1,291,838</u>
<b>NET BOOK VALUE</b>	
As at December 31, 2021	\$ 456,339
<b>As at September 30, 2022</b>	<u>\$ 333,708</u>

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 12. RIGHT OF USE ASSET (continued)

The Company's right-of-use asset relates to the lease of buildings.

The Company entered into an agreement for office space in September 2014 in Richmond, Canada. The agreement did not contain any contingent rent clauses, purchase options or escalation clauses. The term of the lease was 36 months commencing on October 1, 2014. The lease contained an option to renew for an additional 36 months. In February 2017, the Company renewed the lease and added additional office premises. The term of the combined lease was 60 months commencing June 1, 2017. The amended agreement does not contain any contingent rent clauses, purchase options or escalation clauses. The Company entered into a sublease agreement for a portion of office space in September 2019. The term for the sublease agreement was 32 months commencing on October 7, 2019 (see Note 8). The Company terminated the lease and sublease on their expiration on May 31, 2022.

The Company entered into an agreement for office space in September 2014 in Minneapolis, United States. The agreement did not contain any contingent rent clauses, purchase options or escalation clauses. The original term of the lease was 66 months commencing on September 1, 2014. Additional office space was added in July 2015. The term of the combined lease was 69 months commencing on July 1, 2015. In August 2019, the Company renewed the lease for an additional 36 months commencing June 1, 2020.

The Company entered into an agreement for office space in December 2016 in Richmond, Canada. The agreement does not contain any contingent rent clauses, renewal or purchase options or escalation clauses. The term of the lease was 24 months commencing on December 19, 2016. In December 2018, the Company renewed the lease for another 24 months commencing on December 19, 2018. In October 2020, the Company renewed the lease for another 24 months commencing on December 19, 2020. In August 2022, the Company renewed the lease for another 24 months commencing on December 19, 2022.

The Company entered into an agreement for office space in June 2018 in Richmond, Canada. The agreement does not contain any contingent rent clauses, purchase options or escalation clauses. The term of the lease was 36 months commencing on August 1, 2018. The lease contains an option to renew for an additional 24 months. In June 2020, the Company renewed the lease for an additional 36 months commencing August 1, 2021.

## NEOVASC INC.

### Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

#### 13. PROPERTY AND EQUIPMENT

	Leasehold improvements	Production & development equipment	Computer hardware	Computer software	Office equipment	Total
<b>COST</b>						
Balance as at January 1, 2021	\$ 169,938	\$ 1,806,171	\$ 650,071	\$ 726,693	\$ 316,085	\$ 3,668,958
Additions during the year	-	110,987	-	53,094	-	164,081
Disposals during the year	-	(40,661)	-	-	-	(40,661)
Write downs for obsolescence	(111,390)	(1,799,123)	-	-	-	(1,910,513)
Balance at December 31, 2021	\$ 58,548	\$ 77,374	\$ 650,071	\$ 779,787	\$ 316,085	\$ 1,881,865
Additions during the period	-	52,467	-	-	-	52,467
<b>Balance as at September 30, 2022</b>	<b>\$ 58,548</b>	<b>\$ 129,841</b>	<b>\$ 650,071</b>	<b>\$ 779,787</b>	<b>\$ 316,085</b>	<b>\$ 1,934,332</b>
<b>ACCUMULATED DEPRECIATION</b>						
Balance at January 1, 2021	\$ 133,623	\$ 1,242,024	\$ 500,402	\$ 723,920	\$ 265,709	\$ 2,865,678
Depreciation for the year	12,818	85,415	44,900	36,424	10,076	189,633
Disposals during the year	-	(38,596)	-	-	-	(38,596)
Write downs for obsolescence	(87,893)	(1,228,998)	-	-	-	(1,316,891)
Balance at December 31, 2021	\$ 58,548	\$ 59,845	\$ 545,302	\$ 760,344	\$ 275,785	\$ 1,699,824
Depreciation for the period	-	9,087	23,574	14,583	6,045	53,289
<b>Balance at September 30, 2022</b>	<b>\$ 58,548</b>	<b>\$ 68,932</b>	<b>\$ 568,876</b>	<b>\$ 774,927</b>	<b>\$ 281,830</b>	<b>\$ 1,753,113</b>
<b>CARRYING AMOUNTS</b>						
As at December 31, 2021	\$ -	\$ 17,529	\$ 104,769	\$ 19,443	\$ 40,300	\$ 182,041
<b>As at September 30, 2022</b>	<b>\$ -</b>	<b>\$ 60,909</b>	<b>\$ 81,195</b>	<b>\$ 4,860</b>	<b>\$ 34,255</b>	<b>\$ 181,219</b>

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 14. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	September 30, 2022	December 31, 2021
Trade payables	\$ 791,795	\$ 1,434,357
Accrued liabilities	1,340,373	2,113,594
Accrued vacation	374,306	293,553
Share appreciation rights liability	650,106	509,618
Other accounts payable	582,849	278,041
Total accounts payable and accrued liabilities	<u>\$ 3,739,429</u>	<u>\$ 4,629,163</u>

### 15. LEASE LIABILITY

	Total
Balance at January 1, 2021	\$ 939,791
Interest expense	97,337
Lease payments	(491,331)
Balance at December 31, 2021	<u>\$ 545,797</u>
Lease modification	89,932
Interest expense	48,826
Lease payments	(259,635)
<b>Balance at September 30, 2022</b>	<b><u>\$ 424,920</u></b>

#### Presented on the condensed interim consolidated statements of financial position as at September 30, 2022 as:

Lease Liability, current	\$ 224,195
Lease Liability, non-current	\$ 200,725

#### Presented on the condensed interim consolidated statements of financial position as at December 31, 2021 as:

Lease Liability, current	\$ 273,145
Lease Liability, non-current	\$ 272,652

#### The maturity analysis of the undiscounted contractual balances of the lease liabilities is as follows:

In one year or less	\$ 284,437
In more than one year, but not more than five years	215,113
	<u>\$ 499,550</u>



# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 16. DERIVATIVE WARRANT LIABILITY FROM FINANCING AND CONVERTIBLE NOTES

#### (a) 2019 Convertible Notes

On May 16, 2019, the Company completed a private placement of (i) 15% original issue discount convertible notes ("2019 Notes") with a face value of \$11.5 million, for gross proceeds to the Company of \$9,775,000, and (ii) 13,398 Common Shares of the Company at a price of \$128.75 per Common Share, for gross proceeds to the Company of \$1,725,000.

The 2019 Notes have the following key terms:

- For the first year after the closing date, interest at a rate of 8% of which 5% is payable in cash on or about May 17, 2020 (when the existing 2017 Notes issued by the Company mature). The remainder is deferred and will be due on maturity of the 2019 Notes.
- After the first year and until maturity, interest at a rate of 10% of which 7% is payable in cash at the end of May and November each year. The remainder is deferred and will be due on maturity of the 2019 Notes.
- The 2019 Notes were issued at an original discount of \$1.725 million. A separate subscription for Common Shares of the Company by the holder of the 2019 Notes was made for this amount (at market price) concurrent with the issuance of the 2019 Notes.
- The Company has a prepayment option whereby it may voluntarily prepay the 2019 Notes prior to maturity. Prepayment penalties of 3% (if prepaid prior to the 1st anniversary of issuance), 2% (if prepaid between the 1st and 2nd anniversaries of issuance) and 1% (if prepaid after the 2nd anniversary) apply.
- The 2019 Notes are convertible into Common Shares of the Company at the option of the holder (however, the holder may not own > 19.99% of the total outstanding Common Shares of the Company as a result of the conversion). The conversion price fluctuates from \$187.50 per common share (prior to the 2nd anniversary of issuance) to \$212.50 between the 2nd and 3rd anniversaries of issuance to \$242.50 after the 3<sup>rd</sup> anniversary of issuance. The conversion price would also be altered subject to certain anti-dilution provisions.

The 2019 Notes contain two embedded derivatives: the conversion option and the prepayment option. The Company has elected to measure the 2019 Notes at FVTPL. The fair values of the 2019 Notes were calculated using the Cox Ross Rubinstein binomial tree model and have been classified as level 3 in the fair value hierarchy.

On March 23, 2022, the 2019 Notes were extinguished as the Company issued restated senior secured convertible notes ("2022 Notes") with a principal amount of \$13 million to consolidate the 2019 Notes and 2020 senior secured convertible notes ("2020 Notes") (see Note 16(c)).

#### (b) 2020 Convertible Notes

On May 28, 2020, the Company issued 2020 Notes with a principal amount of \$5 million, convertible at \$70.38 per Common Share for 71,042 Common Shares and 102,958 Warrants ("May 2020 Warrants") exercisable at \$65.85 per 2020 Warrant with a 4-year term.

The 2020 Notes have the following key terms:

- The 2020 Notes will bear interest at the rate of 8% computed on the basis of a 360-day year and twelve 30-day months and shall be payable in additional 2020 Notes on the date that is six-months after issuance and on each six-month period thereafter up to, and including, the maturity date.
- The 2020 Notes will have a maturity date of 48 months after issuance with the holder's option for early redemption at 24 months.
- Change of control redemption option with option premia of 125% in the first year, 115% in the second year, 105% in the third year, and 100% thereafter.
- The 2020 Notes are convertible into Common Shares of the Company at the option of the holder (however, the holder may not own greater than 9.99% of the total outstanding Common Shares of the Company as a result of the conversion).
- The conversion option caused the number of shares to be issued upon exercise to be variable, and therefore do not meet the fixed of fixed test under IAS 32- Financial instruments – presentation.

The 2020 Notes contain three embedded derivatives: change in control redemption option, the early redemption option and the conversion option, but will not be separated from the host debt instrument and the entire hybrid contract will be designated as at fair value through profit or loss. The fair values of the 2020 Notes and 2020 Warrants were calculated using the Cox Ross Rubinstein binomial tree model and have been classified as level 3 in the fair value hierarchy. The fair value of the convertible debt was \$6,449,634 which exceeded the transaction price giving rise to a loss of \$3,511,670. Since the fair value of the convertible debt is not determined using a valuation that only uses data from observable markets, the loss on initial recognition has been deferred and will be recognized in income over the expected term of the instrument.

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 16. DERIVATIVE WARRANT LIABILITY FROM FINANCING AND CONVERTIBLE NOTES (continued)

#### (b) 2020 Convertible Notes (continued)

On March 23, 2022, the 2020 Notes were extinguished as the Company issued 2022 Notes with a principal amount of \$13 million to consolidate the 2019 Notes and 2020 Notes (see Note 16(c)).

#### (c) 2022 Convertible Notes

On March 23, 2022 the Company issued 2022 Notes with a principal amount of \$13 million to consolidate the 2019 Notes and 2020 Notes.

The 2022 Notes have the following key terms:

- The 2022 Notes will bear interest at the rate of 9% per annum, compounded quarterly, of which 4% is paid semi-annually, and 5% is added to the principal.
- The 2022 Notes will have a maturity date of December 31, 2025.
- The 2022 Notes are convertible into common shares at a price of \$25.00 per common share (however, the holder may not own greater than 9.99% of the total outstanding Common Shares of the Company as a result of the conversion).
- The conversion option caused the number of shares to be issued upon exercise to be fixed, and therefore meets the fixed for fixed test under IAS 32- Financial instruments – presentation.
- The Company can prepay any portion of the principal amount (and any related interest accrued on the principal being prepaid) at any time prior to the maturity date, provided that they pay the following penalties:
  - 3% of the principal if the prepayment is made within one year of the closing of the 2022 convertible note
  - 2% of the principal if the prepayment is made between the first and second years from the closing of the 2022 convertible note; and
  - 1% of the principal if the prepayment is made after the second year from the closing of the 2022 convertible note
- Upon prepayment, the Company will issue common share purchase warrants. The number of warrants issued is equal to the amount of the prepayment divided by the conversion price. Each warrant is exercisable into one common share and will have an exercise price equal to the conversion price and expire on the maturity date.
- Upon a change in control event, the Company may be required to prepay the outstanding principal and interest.

The Company elected to measure the 2022 Notes initially at fair value and subsequently at amortized cost. The 2022 Notes contain two embedded derivatives: the change in control prepayment option and the prepayment option. The change in control prepayment option is not accounted for as a separate embedded derivative. The prepayment option is accounted for as a separate embedded derivative and is measured initially and subsequently at fair value through profit and loss.

The estimated fair value of the 2022 Notes on March 23, 2022 is \$12,519,876. The estimated fair value relating to the equity conversion option, recognized in equity, is \$974,136. The remaining balance of \$11,545,740 was recognized as a liability.

The fair values of 2019 Notes, 2020 Notes and 2022 Notes on March 23, 2022 were calculated based on the level 3 fair value estimate of the notes based on a binomial tree model.

Key assumptions used in the model at March 23, 2022 are summarized below:

Valuation Date	2019 Notes	2020 Notes	2022 Notes
Price of Common Shares	\$ 0.41	\$ 0.41	\$ 0.41
Dividend Yield	0%	0%	0%
Historical volatility of Common Shares	77.54%	89.25%	95.21%
Historical volatility of index	12.83%	22.97%	19.89%
Volatility input	45.19%	56.11%	57.55%
Risk-free rate	1.90%	2.34%	2.39%
Credit spread	10.41%	7.97%	9.36%

The recognition of the 2022 Notes and extinguishment of the 2019 Notes and 2020 Notes resulted in a realized loss of \$1,881,651.

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 16. DERIVATIVE WARRANT LIABILITY FROM FINANCING AND CONVERTIBLE NOTES (continued)

#### (d) Warrants and Convertible Notes Model

The 2019 Notes were accounted for based on the level 3 fair value estimate of the notes based on a binomial tree model.

Key assumptions used in the model at December 31, 2021 are summarized below:

Valuation Date	December 31, 2021
Price of Common Shares	\$ 0.47
Dividend Yield	0%
Historical volatility of Common Shares	93.47%
Historical volatility of index	13.44%
Volatility input	53.45%
Risk-free rate	0.67%
Credit spread	14.89%

The 2020 Notes were accounted for based on the level 3 fair value estimate of the notes based on a binomial tree model.

Key assumptions used in the model at December 31, 2021 are summarized below:

Valuation Date	December 31, 2021
Price of Common Shares	\$ 0.47
Dividend Yield	0%
Historical volatility of Common Shares	91.91%
Historical volatility of index	21.86%
Volatility input	56.89%
Risk-free rate	1.02%
Credit spread	11.13%

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 16. DERIVATIVE WARRANT LIABILITY FROM FINANCING AND CONVERTIBLE NOTES (continued)

#### (d) Warrants and Convertible Notes Model (continued)

	<b>2019 Convertible Notes</b>	
<b>Balance, convertible notes January 1, 2021</b>	<b>\$</b>	<b>6,195,357</b>
Fair value adjustment, unrealized loss		104,038
Fair value adjustment, unrealized loss due to changes in credit spread		288,034
<b>Balance, convertible notes December 31, 2021</b>	<b>\$</b>	<b>6,587,429</b>
Fair value adjustment, unrealized loss		91,874
Fair value adjustment, realized loss		106,884
Fair value adjustment, unrealized loss due to changes in credit spread		282,009
Derecognition of convertible notes		(7,068,196)
<b>Balance, convertible notes September 30, 2022</b>	<b>\$</b>	<b>-</b>

#### Presented on the condensed interim consolidated statements of financial position as:

	<b>September 30, 2022</b>	<b>December 31, 2021</b>
<b>2019 Convertible Notes, current</b>	<b>\$ -</b>	<b>\$ 38,633</b>
<b>2019 Convertible Notes, non-current</b>	<b>\$ -</b>	<b>\$ 6,548,796</b>

	<b>2020 Convertible Notes</b>	
<b>Balance, convertible notes January 1, 2021</b>	<b>\$</b>	<b>2,616,202</b>
Amortization of deferred loss		877,916
Fair value adjustment, unrealized gain		(18,134)
Fair value adjustment, realized loss		3,062
Fair value adjustment, unrealized gain due to changes in credit spread		(18,726)
<b>Balance, convertible notes December 31, 2021</b>	<b>\$</b>	<b>3,460,320</b>
Amortization of deferred loss		216,473
Fair value adjustment, unrealized loss		248,836
Fair value adjustment, realized gain		(142,713)
Fair value adjustment, unrealized gain due to changes in credit spread		(65,071)
Derecognition of convertible notes		(3,717,845)
<b>Balance, convertible notes September 30, 2022</b>	<b>\$</b>	<b>-</b>

The carrying amounts for the 2020 derivative warrant liability from financing are as follows:

	<b>January 2020 Warrants</b>	
<b>Balance, January 1, 2021</b>	<b>\$</b>	<b>11,347</b>
Amortization of deferred loss		20,504
Fair value adjustment, unrealized gain		(1,616)
<b>Balance, December 31, 2021</b>	<b>\$</b>	<b>30,235</b>
Amortization of deferred loss		15,336
Fair value adjustment, unrealized gain		(296)
<b>Balance, September 30, 2022</b>	<b>\$</b>	<b>45,275</b>
Number of warrants outstanding as of September 30, 2022		10,000

	<b>May 2020 Warrants</b>	
<b>Balance, January 1, 2021</b>	<b>\$</b>	<b>(256,639)</b>
Amortization of deferred loss		141,414
Fair value adjustment, unrealized gain		(231,862)
<b>Balance, December 31, 2021</b>	<b>\$</b>	<b>(347,087)</b>
Amortization of deferred loss		105,770
Fair value adjustment, unrealized gain		(5,590)
<b>Balance, September 30, 2022</b>	<b>\$</b>	<b>(246,907)</b>
Number of warrants outstanding as of September 30, 2022		25,956

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 16. DERIVATIVE WARRANT LIABILITY FROM FINANCING AND CONVERTIBLE NOTES (continued)

#### (d) Warrants and Convertible Notes Model (continued)

	<u>June 2020 Warrants</u>
<b>Balance, January 1, 2021</b>	<b>\$ (49,176)</b>
Amortization of deferred loss	180,220
Fair value adjustment, unrealized gain	(235,947)
<b>Balance, December 31, 2021</b>	<b>\$ (104,903)</b>
Amortization of deferred loss	36,651
Fair value adjustment, unrealized gain	(38,569)
<b>Balance, September 30, 2022</b>	<b>\$ (106,821)</b>
Number of warrants outstanding as of September 30, 2022	116,489
	<u>August 2020 Warrants</u>
<b>Balance, January 1, 2021</b>	<b>\$ (2,195,092)</b>
February 12 exercise of 125,000 warrants	(80,856)
Derecognition of deferred loss	87,118
Fair value adjustment, February 12 realized gain	(48,244)
Amortization of deferred loss	1,250,393
Fair value adjustment, unrealized gain	(177,403)
<b>Balance, December 31, 2021</b>	<b>\$ (1,164,084)</b>
Amortization of deferred loss	303,971
Fair value adjustment, unrealized gain	(47,377)
<b>Balance, September 30, 2022</b>	<b>\$ (907,490)</b>
Number of warrants outstanding as of September 30, 2022	130,977
	<u>December 2020 Warrants</u>
<b>Balance, January 1, 2021</b>	<b>\$ 1,184,291</b>
February 12 exercise of 1,828,479 warrants	(2,545,349)
Derecognition of deferred loss	341,242
Fair value adjustment, February 12 realized loss	1,943,274
Amortization of deferred loss	401,539
Fair value adjustment, unrealized gain	(1,375,260)
<b>Balance, December 31, 2021</b>	<b>\$ (50,263)</b>
Amortization of deferred loss	123,584
Fair value adjustment, unrealized gain	(331,883)
<b>Balance, September 30, 2022</b>	<b>\$ (258,562)</b>
Number of warrants outstanding as of September 30, 2022	176,090
	<u>2020 Repayment Warrants</u>
<b>Balance, January 1, 2021</b>	<b>\$ 9,448</b>
Fair value adjustment, unrealized gain	(9,374)
<b>Balance, December 31, 2021</b>	<b>\$ 74</b>
Fair value adjustment, unrealized gain	(73)
<b>Balance, September 30, 2022</b>	<b>\$ 1</b>
Number of warrants outstanding as of September 30, 2022	26,011
	<u>2020 Settlement Warrants</u>
<b>Balance, January 1, 2021</b>	<b>\$ 201,673</b>
Fair value adjustment, unrealized gain	(197,134)
<b>Balance, December 31, 2021</b>	<b>\$ 4,539</b>
Fair value adjustment, unrealized gain	(2,037)
<b>Balance, September 30, 2022</b>	<b>\$ 2,502</b>
Number of warrants outstanding as of September 30, 2022	19,996

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 16. DERIVATIVE WARRANT LIABILITY FROM FINANCING AND CONVERTIBLE NOTES (continued)

#### (d) Warrants and Convertible Notes Model (continued)

The following table lists 2020 warrants and derivative warrant liabilities outstanding as at September 30, 2022:

Derivative liability – 2020 January warrants	\$	45,275
Derivative liability – 2020 May warrants		(246,907)
Derivative liability – 2020 June warrants		(106,821)
Derivative liability – 2020 August warrants		(907,490)
Derivative liability – 2020 December warrants		(258,562)
Derivative liability – 2020 Repayment warrants		1
Derivative liability – 2020 Settlement warrants		2,502
<b>Balance, 2020 Warrants and derivative liabilities September 30, 2022</b>	<b>\$</b>	<b>(1,472,002)</b>

Presented on the condensed interim consolidated statements of financial position as:

<b>Deferred loss on 2020 derivative warrant liabilities</b>	<b>\$</b>	<b>1,598,357</b>
<b>2020 Derivative warrant liabilities</b>	<b>\$</b>	<b>126,355</b>

The following table lists 2020 convertible notes and warrants and derivative warrant liabilities outstanding as at December 31, 2021:

Convertible notes – 2020 Convertible notes	\$	3,460,320
Derivative liability – 2020 January warrants		30,235
Derivative liability – 2020 May warrants		(347,087)
Derivative liability – 2020 June warrants		(104,903)
Derivative liability – 2020 August warrants		(1,164,084)
Derivative liability – 2020 December warrants		(50,263)
Derivative liability – 2020 Repayment warrants		74
Derivative liability – 2020 Settlement warrants		4,539
<b>Balance, 2020 Convertible notes and warrants and derivative liabilities December 31, 2021</b>	<b>\$</b>	<b>1,828,831</b>

Presented on the condensed interim consolidated statements of financial position as:

<b>Deferred loss on 2020 derivative warrant liabilities</b>	<b>\$</b>	<b>4,300,484</b>
<b>2020 Convertible notes, warrants and derivative liabilities, current</b>	<b>\$</b>	<b>40,587</b>
<b>2020 Convertible notes, warrants and derivative liabilities, non-current</b>	<b>\$</b>	<b>6,088,728</b>

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 16. DERIVATIVE WARRANT LIABILITY FROM FINANCING AND CONVERTIBLE NOTES (continued)

#### (d) Warrants and Convertible Notes Model (continued)

The carrying amounts for the 2021 derivative warrant liability from financing are as follows:

	<b>February 2021 Warrants</b>	
Inception of the February 2021 Warrants (see Note 17(e))	\$	15,666,819
Deferred loss		(15,666,819)
Amortization of deferred loss		5,768,343
Fair value adjustment, unrealized gain		(15,261,310)
<b>Balance, December 31, 2021</b>	<b>\$</b>	<b>(9,492,967)</b>
Amortization of deferred loss		2,469,531
Fair value adjustment, unrealized gain		(347,899)
<b>Balance, September 30, 2022</b>	<b>\$</b>	<b>(7,371,335)</b>
Number of warrants outstanding as of September 30, 2022		719,998

#### Presented on the condensed interim consolidated statements of financial position as:

	<b>September 30, 2022</b>	<b>December 31, 2021</b>
<b>Deferred loss on 2021 derivative warrant liabilities</b>	<b>\$ 7,428,944</b>	<b>\$ 9,898,475</b>
<b>2021 Derivative warrant liabilities</b>	<b>\$ 57,609</b>	<b>\$ 405,508</b>

	<b>2022 Convertible Notes</b>	
Fair value, March 23, 2022	\$	11,545,740
Interest expense		760,747
Payments		(141,319)
<b>Balance, 2022 Convertible notes September 30, 2022, non-current</b>	<b>\$</b>	<b>12,165,168</b>

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 17. SHARE CAPITAL

All Common Shares are equally eligible to receive dividends and the repayment of capital and represent one vote at shareholders' meetings. All Preferred Shares have no voting rights at shareholders' meetings but on liquidation, winding-up or other distribution of the Company's assets are entitled to participate in priority to Common Shares. There are no Preferred Shares issued and outstanding.

#### (a) Authorized

Unlimited number of Common Shares without par value.

Unlimited number of Preferred Shares without par value.

The Company may issue its Preferred Shares from time to time in one or more series. The terms of each series of Preferred Shares, including the number of shares, the designation, rights, preferences, privileges, priorities, restrictions, conditions and limitations, will be determined at the time of creation of each such series by our board of directors, without shareholder approval, provided that all Preferred Shares will rank equally within their class as to dividends and distributions in the event of our dissolution, liquidation or winding-up.

	Common Shares		Contributed
	Number	Amount	Surplus
<b>Balance, January 1, 2021</b>	<b>1,157,157</b>	<b>\$ 369,775,383</b>	<b>\$ 35,045,056</b>
Common Shares issued from public offering (i)	1,440,000	72,000,000	-
Transaction costs for public offering	-	(5,131,089)	-
Broker warrants (see Note 17 (e))	-	(1,898,959)	1,898,959
Common Shares issued from on exercise of warrants (ii)	5,000	417,092	-
Common Shares issued from on exercise of warrants (iii)	73,139	3,287,736	-
Common Shares issued from vesting of restricted share units (iv)	30,893	1,423,294	(1,423,294)
Share-based payments	-	-	4,835,231
<b>Balance, December 31, 2021</b>	<b>2,706,189</b>	<b>\$ 439,873,457</b>	<b>\$ 40,355,952</b>
Issue of 2022 Convertible notes	-	-	974,136
Common Shares issued from vesting of restricted share units (v)	40,061	1,276,863	(1,276,863)
Common Shares issued from exercise of stock options (v)	375	3,667	(1,478)
Share-based payments	-	-	2,439,443
<b>Balance, September 30, 2022</b>	<b>2,746,625</b>	<b>\$ 441,153,987</b>	<b>\$ 42,491,190</b>

- (i) On February 12, 2021, the Company completed a registered direct offering of an aggregate 1,440,000 units at a price of \$50.00 per unit for aggregate gross proceeds to the Company of \$72,000,000 less \$5,760,000 in underwriting commission, a \$1,898,959 fair value charge for compensation warrants, and \$917,900 in other share issuance costs, of which \$7,030,048 has been capitalized and \$1,546,811 has been expensed through the income statement.
- (ii) Between January 1, 2021 and March 31, 2021, 5,000 Common Shares were issued on the exercise of warrants in connection with the August 2020 Financing.
- (iii) Between January 1, 2021 and March 31, 2021, 73,139 Common Shares were issued on the exercise of warrants in connection with the December 2020 Financing.
- (iv) During the year ended December 31, 2021, 30,893 Common Shares were issued for the vesting of RSUs.
- (v) During the nine months ended September 30, 2022, 40,436 Common Shares were issued for the vesting of RSUs and exercise of stock options



# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 17. SHARE CAPITAL (continued)

#### (b) Stock options

The Company adopted an equity-settled stock option plan under which the directors of the Company may grant options to purchase Common Shares to directors, officers, employees and service providers (the “optionees”) of the Company on terms that the directors of the Company may determine within the limitations set forth in the stock option plan. Effective June 4, 2018, at the Annual General Meeting (“AGM”), the board of directors and shareholders of the Company approved an amendment to the Company’s incentive stock option plan to increase the number of options available for grant under the plan to 15% of the number of Common Shares of the Company outstanding at any time.

Options under the Company’s stock option plan granted to directors, officers and employees vest immediately on the grant date, unless a vesting schedule is specified by the board. The directors of the Company have discretion within the limitations set forth in the stock option plan to determine other vesting terms on options granted to directors, officers, employees, and others. The minimum exercise price of a stock option cannot be less than the applicable market price of the Common Shares on the date of the grant, and the options have a maximum life of ten years from the date of grant. The following table summarizes stock option activity for the respective years as follows:

	Number of options	Weighted average exercise price	Average remaining contractual life (years)
<b>Options outstanding, January 1, 2021</b>	<b>123,058</b>	<b>\$ 95.04</b>	<b>7.19</b>
<b>Options exercisable, January 1, 2021</b>	<b>43,267</b>	<b>\$ 134.46</b>	<b>6.93</b>
Granted	239,722	\$ 27.33	
Cancelled/Forfeited	(78,671)	\$ 82.41	
<b>Options outstanding, December 31, 2021</b>	<b>284,109</b>	<b>\$ 41.32</b>	<b>7.25</b>
<b>Options exercisable, December 31, 2021</b>	<b>75,127</b>	<b>\$ 69.43</b>	<b>6.90</b>
Granted	90,150	\$ 5.91	
Exercised	(375)	\$ 5.84	
Cancelled/Forfeited	(14,242)	\$ 114.80	
Expired	(5)	\$ 34,337.75	
<b>Options outstanding, September 30, 2022</b>	<b>359,637</b>	<b>\$ 29.09</b>	<b>6.83</b>
<b>Options exercisable, September 30, 2022</b>	<b>128,714</b>	<b>\$ 41.00</b>	<b>6.54</b>

The following table lists the options outstanding as at September 30, 2022 by exercise price:

Exercise price	Options outstanding	Weighted average remaining term (yrs)	Options exercisable	Weighted average remaining term (yrs)
\$5.84	72,838	7.68	18,544	7.68
\$5.95	5,250	7.68	1,315	7.68
\$6.50	9,250	7.97	2,313	7.97
\$15.00	67,372	7.21	13,458	7.21
\$18.00	4,440	7.17	-	-
\$21.00	22,040	6.88	5,510	6.88
\$34.50	119,320	6.46	47,932	6.46
\$34.51 - \$15,750	59,127	5.77	39,642	5.70
	<b>359,637</b>		<b>128,714</b>	

The following table lists the options outstanding as at December 31, 2021 by exercise price:

Exercise price	Options outstanding	Weighted average remaining term (yrs)	Options exercisable	Weighted average remaining term (yrs)
\$15.00	68,402	7.96	13,597	7.96
\$18.00	5,280	7.92	-	-
\$21.00	22,040	7.62	-	-
\$34.50	121,610	7.21	24,792	7.21
\$52.75 - \$37,596.25	66,777	6.42	36,738	6.31
	<b>284,109</b>		<b>75,127</b>	

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 17. SHARE CAPITAL (continued)

#### (b) Stock Options (continued)

During the three and nine months ended September 30, 2022, the Company recorded an expense of \$425,967 and \$1,355,887 for share-based compensation awarded to eligible optionees (expense recorded for the three and nine months ended September 30, 2021: \$597,961 and \$2,240,188). The Company used the Black-Scholes Option Pricing Model to estimate the fair value of the options at each measurement date using the following weighted average assumptions:

	September 30, 2022	December 31, 2021
Weighted average fair value	\$ 3.99	\$ 20.46
Weighted average exercise price	\$ 5.91	\$ 27.33
Weighted average share price at grant	\$ 5.91	\$ 27.33
Dividend yield	Nil	Nil
Volatility	113%	117%
Risk-free interest rate	1.32%	0.91%
Expected life	4 years	4 years
Forfeiture rate	11%	7%

#### (c) Restricted share units

On December 2, 2019, the Company adopted a Restricted Share Unit ("RSU") Plan which provides for RSUs to be awarded to directors, officers, employees and service providers. The maximum number of Common Shares authorized and reserved for issuance under the RSU Plan is equal to 5% of the issued and outstanding Common Shares of the Company. The shareholders of the Company approved the amended RSU Plan at the annual meeting of the shareholders on September 3, 2020, which falls within 12 months of the effective date of the RSU Plan.

The granting of RSUs is considered an equity-settled share-based payment transaction. The fair value of the grant was determined by multiplying the Company's share price at the grant date by the number of RSUs granted and is recognized over the vesting period of the grant. The expense recognized for the three and nine months ended September 30, 2022, was \$293,718 and \$1,083,556 (three and nine months ended September 30, 2021: \$485,120 and \$1,911,969). As of September 30, 2022, the total remaining unrecognized compensation cost related to RSUs amounted to approximately \$1,090,169 which will be amortized over the remaining vesting periods.

RSU transactions are summarized as follows:

	Number of RSUs	Weighted Average Grant Date Fair Value Per Share
<b>Outstanding, January 1, 2021</b>	<b>31,119</b>	<b>\$69.08</b>
Granted	116,000	\$33.10
Vested	(30,880)	\$46.06
Cancelled/Forfeited	(10,083)	\$45.19
<b>Outstanding, December 31, 2021</b>	<b>106,156</b>	<b>\$41.33</b>
Granted	43,500	\$5.84
Vested	(40,067)	\$31.85
Cancelled/Forfeited	(38)	\$69.00
<b>Outstanding, September 30, 2022</b>	<b>109,551</b>	<b>\$33.36</b>

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 17. SHARE CAPITAL (continued)

#### (d) Share appreciation rights

On September 22, 2020, the Company adopted a Share Appreciation Rights (“SAR”) Plan which provides for SARs to be awarded to directors, officers, employees and service providers. The granting of SARs is considered a cash-settled payment transaction. The fair value of the SAR is measured applying a Black-Scholes Option Pricing Model, taking into account the terms and conditions on which the SARs are granted. As the exercise price of SARs is \$0.00, the fair value equals the outstanding units multiplied by the share price at the reporting date. The liability of the SAR is measured initially at grant date and at the end of each reporting period until settled. The fair value of the SAR as of September 30, 2022, is \$2,186,710 which will be recorded over the vesting period of the SAR. The Company recognized an expense of \$201,915 and \$140,487, for the three and nine months ended September 30, 2022 (expense recognized for the three and nine months ended September 30, 2021: \$700,594 and \$2,082,594).

SAR transactions are summarized as follows:

	Number of SARs	Weighted Average Grant Date Fair Value Per Share
<b>Outstanding, January 1, 2021</b>	<b>72,471</b>	<b>\$4.63</b>
Granted	224,000	\$0.000
Cancelled	(72,471)	\$4.63
<b>Outstanding, December 31, 2021</b>	<b>224,000</b>	<b>\$0.000</b>
Granted	99,000	\$0.000
<b>Outstanding, September 30, 2022</b>	<b>323,000</b>	<b>\$0.000</b>

#### (e) Warrants

On January 6, 2020, the Company completed a registered direct offering of an aggregate of 47,400 series A units (“Series A Units”) and 49,660 series B units (“Series B Units”): Series B Units at a price of \$103.38 per Series A Unit and \$103.38 per Series B Unit for aggregate gross proceeds to the Company of \$10,053,474. Each Series A Unit consists of one Common Share of Neovasc and one warrant (“January 2020 Warrant”). Each January 2020 Warrant entitles the holder to acquire one Common Share of Neovasc at a price of \$103.38 at any time prior to four years following the date of issuance. Each Series B Unit consists of one pre-funded warrant (“Pre-Funded Warrant”) of Neovasc and one January 2020 Warrant. Each Pre-Funded Warrant entitles the holder to acquire one Common Share of Neovasc at a price of \$0.0025 at any time until the exercise in full of each Pre-Funded Warrant.

All Pre-Funded Warrants were exercised between January 6, 2020 and March 31, 2020. The January 2020 Warrants include a cashless exercise option which is effective only if the Company does not have an effective registration statement in the United States at the time of the exercise. In accordance with IAS 32 – Financial instruments; presentation, the January 2020 Warrants have been accounted for as derivative financial liabilities and measured at FVTPL. The fair value at issuance date of \$6,145,620 for the January 2020 Warrants and Pre-Funded Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 1.60%; b) expected life of 1 years; c) the price of the stock on the grant date of \$86.75; d) expected volatility of 70%; and e) no expected dividend payments. The fair value on September 30, 2022 of \$1 for the January 2020 Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 3.44%; b) expected life of 1.25 years; c) the price of the stock on September 30, 2022 of \$6.77; d) expected volatility of 53.65%; and e) no expected dividend payments.

On May 28, 2020, the Company issued an aggregate of 26,917 shares (“Exchange Shares”) for the surrender and cancellation of 87,060 January 2020 Warrants outstanding on the basis of approximately 0.3092 of an Exchange Share for each warrant. Subsequent to the exchange, 10,000 January 2020 Warrants remain outstanding.

On May 26, 2020, the Company granted 102,958 warrants with an exercise price of \$65.85 and term of 4 years (“May 2020 Warrants”). The May 2020 Warrants are convertible into Common Shares of the Company at the option of the holder (however, the holder may not own greater than 9.99% of the total outstanding Common Shares of the Company as a result of the conversion). The May 2020 Warrants include a cashless exercise option which is effective only if the Company does not have an effective registration statement in the United States at the time of the exercise. In accordance with IAS 32 – Financial instruments; presentation, the May 2020 Warrants have been accounted for as derivative financial liabilities and measured at FVTPL. The fair value at issuance date of \$4,526,732 of the May 2020 Warrants were calculated using a binomial option pricing model and have been classified as level 3 in the fair value hierarchy. On July 23, 2020, 56,962 May 2020 Warrants were exercised, and on August 17, 2020, 20,040 May 2020 Warrants were exercised, leaving 25,956 May

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 17. SHARE CAPITAL (continued)

#### (e) Warrants (continued)

2020 Warrants remaining. The total exercise proceeds of \$4,877,225, net of interest and prepayment penalty, has been applied to the principal of the 2019 Note.

The fair value on September 30, 2022 of \$199 for the May 2020 Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 3.44%; b) expected life of 2 years; c) the price of the stock on September 30, 2022 of \$6.77; d) expected volatility of 53.65%; and e) no expected dividend payments.

On May 28, 2020 the Company entered into a settlement agreement to issue 20,000 settlement warrants ("2020 Settlement Warrants"). Each Settlement Warrant entitles the holder to purchase one Common Share in the capital of the Company at an exercise price of \$65.85 per Settlement Warrant for a period of 4 years following issuance and are subject to transfer/leak-out restrictions, including volume and public float restrictions. The 2020 Settlement Warrants include a cashless exercise option which is effective only if the Company does not have an effective registration statement in the United States at the time of the exercise. In accordance with IAS 32 – Financial instruments; presentation, the 2020 Settlement Warrants have been accounted for as derivative financial liabilities and measured at FVTPL. The fair value at issuance date of \$807,977 of the 2020 Settlement Warrants were calculated using the Cox Ross Rubinstein binomial tree model and have been classified as level 3 in the fair value hierarchy. The fair value on September 30, 2022 of \$2,502 of the 2020 Settlement Warrants were calculated using the Cox Ross Rubinstein binomial tree model and have been classified as level 3 in the fair value hierarchy.

On June 16, 2020, the Company completed a registered direct offering of an aggregate 155,321 units (the "June 2020 Units") at a price of \$74.33 per unit for aggregate gross proceeds to the Company of \$11,544,266 less \$1,215,274 in underwriting commission, a \$162,467 fair value charge for compensation warrants ("June 2020 Compensation Warrants"), and \$278,482 in other share issuance costs. Each June 2020 Unit consists of one Common Share of the Company and three-quarters of one warrant (each whole warrant, a "June 2020 Warrant") to purchase one Common Share issuing 116,491 June 2020 Warrants in total. Each June 2020 Warrant entitles the holder to acquire one Common Share of the Company at a price of \$72.00 at any time prior to June 16, 2025. The June 2020 Warrants include a cashless exercise option which is effective only if the Company does not have an effective registration statement in the United States at the time of the exercise. In accordance with IAS 32 – Financial instruments; presentation, the June 2020 Warrants have been accounted for as derivative financial liabilities and measured at FVTPL. The fair value at issuance date of \$2,404,957 for the June 2020 Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 0.32%; b) expected life of 2 years; c) the price of the stock on the grant date of \$61.75; d) expected volatility of 70%; and e) no expected dividend payments. The fair value on September 30, 2022 of \$3,435 for the June 2020 Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 3.44%; b) expected life of 2.75 years; c) the price of the stock on September 30, 2022 of \$6.77; d) expected volatility of 53.65%; and e) no expected dividend payments.

On July 23, 2020, the Company issued repayment warrants ("July 2020 Repayment Warrants") to purchase up to 19,271 Common Shares at an exercise price of \$187.50 per Common Share at any time prior to July 23, 2025. The exercise price is adjusted as the conversion price of the 2019 Note is adjusted. The fair value at issuance date of \$134,718 for the July 2020 Repayment Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 0.29%; b) expected life of 2 years; c) the price of the stock on the grant date of \$63.50; d) expected volatility of 70%; and e) no expected dividend payments. The fair value on September 30, 2022 of \$0.23 for the July 2020 Repayment Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 3.44%; b) expected life of 2 years; c) the price of the stock on September 30, 2022 of \$6.77; d) expected volatility of 53.65%; and e) no expected dividend payments.

On August 12, 2020, the Company completed a registered direct offering of an aggregate 181,311 units ("August 2020 Units") at a price of \$69.38 per unit for aggregate gross proceeds to the Company of \$12,578,442 less \$1,057,302 in underwriting commission, a \$242,989 fair value charge for Compensation Warrants ("August 2020 Compensation Warrants"), and \$109,918 in other share issuance costs. Each August 2020 Unit consists of one Common Share of the Company and three-quarters of one warrant (each whole warrant, an "August 2020 Warrant") issuing 135,983 August 2020 Warrants in total. Each August 2020 Warrant entitles the holder to acquire one Common Share of the Company at an exercise price of \$67.25 per share at any time prior to August 12, 2025. The August 2020 Warrants include a cashless exercise option which is effective only if the Company does not have an effective registration statement in the United States at the time of the exercise. In accordance with IAS 32 – Financial instruments; presentation, the August 2020 Warrants have been accounted for as derivative financial liabilities and measured at FVTPL. The fair value at issuance date of \$3,511,115 for the August 2020 Warrants was computed using the Black-Scholes pricing model with the following

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 17. SHARE CAPITAL (continued)

#### (e) Warrants (continued)

assumptions: a) average risk-free interest rate of 0.32%; b) expected life of 2 years; c) the price of the stock on the grant date of \$67.50; d) expected volatility of 70%; and e) no expected dividend payments. 5,000 August 2020 Warrants have been exercised and there are 130,977 August 2020 Warrants outstanding at September 30, 2022.

The fair value on September 30, 2022 of \$6,931 for the August 2020 Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 3.44%; b) expected life of 3 years; c) the price of the stock on September 30, 2022 of \$6.77; d) expected volatility of 53.65%; and e) no expected dividend payments.

On August 17, 2020, the Company issued repayment warrants ("August 2020 Repayment Warrants"), the July 2020 Repayment Warrants and the August 2020 Repayment Warrants collectively referred to as the "2020 Repayment Warrants") to purchase up to 6,741 Common Shares at an exercise price of \$187.50 per Common Share at any time prior to August 17, 2025. The exercise price is adjusted as the conversion price of the 2019 Note is adjusted. The fair value at issuance date of \$27,002 for the August 2020 Repayment Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 0.31%; b) expected life of 2 years; c) the price of the stock on the grant date of \$53.25; d) expected volatility of 68%; and e) no expected dividend payments. The fair value on September 30, 2022 of \$0.08 for the August 2020 Repayment Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 3.44%; b) expected life of 2 years; c) the price of the stock on September 30, 2022 of \$6.77; d) expected volatility of 53.65%; and e) no expected dividend payments.

On December 8, 2020, the Company completed a registered direct offering of an aggregate 249,232 units ("December 2020 Units") at a price of \$24.50 per unit for aggregate gross proceeds to the Company of \$6,106,810 less \$659,410 in underwriting commission, a \$96,114 fair value charge for compensation warrants ("December 2020 Compensation Warrants"), and \$178,968 in other share issuance costs. Each December 2020 Unit consists of one Common Share of the Company and one warrant (a "December 2020 Warrant") to purchase one Common Share issuing 249,232 December 2020 Warrants in total. Each December Warrant entitles the holder to acquire one Common Share of the Company at an exercise price of \$21.50 per share at any time prior to December 8, 2025. The December 2020 Warrants include a cashless exercise option which is effective only if the Company does not have an effective registration statement in the United States at the time of the exercise. In accordance with IAS 32 – Financial instruments; presentation, the December 2020 Warrants have been accounted for as derivative financial liabilities and measured at FVTPL. The fair value at issuance date of \$2,051,657 for the December 2020 Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 0.33%; b) expected life of 2 years; c) the price of the stock on the grant date of \$21.50; d) expected volatility of 70%; and e) no expected dividend payments. 148,971 December 2020 Warrants have been exercised and there are 176,090 December 2020 Warrants outstanding at September 30, 2022. The fair value on September 30, 2022 of \$113,209 for the December 2020 Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 3.44%; b) expected life of 3 years; c) the price of the stock on September 30, 2022 of \$6.77; d) expected volatility of 53.65%; and e) no expected dividend payments.

On February 12, 2021 the Company completed a registered direct offering of an aggregate 1,440,000 units ("February 2021 Units") at a price of \$50 per unit for aggregate gross proceeds to the Company of \$72,000,000 less \$5,760,000 in underwriting commission, a \$1,898,959 fair value charge for compensation warrants ("February 2021 Compensation Warrants"), and \$917,900 in other share issuance costs. February 2021 Units consists of one Common Share of the Company and one half of one warrant (each whole warrant, a "February 2021 Warrant") issuing 720,000 February 2021 Warrants in total. Each February 2021 Warrant entitles the holder to acquire one Common Share of the Company at an exercise price of \$57.50 per share at any time prior to February 12, 2026. The February 2021 Warrants include a cashless exercise option which is effective only if the Company does not have an effective registration statement in the United States at the time of the exercise. In accordance with IAS 32 – Financial instruments; presentation, the February 2021 Warrants have been accounted for as derivative financial liabilities and measured at FVTPL. The fair value at issuance date of \$15,666,819 for the February 2021 Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 0.33%; b) expected life of 2 years; c) the price of the stock on the grant date of \$57.25; d) expected volatility of 70%; and e) no expected dividend payments. The fair value on September 30, 2022 of \$57,608 for the February 2021 Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 3.44%; b) expected life of 3 years; c) the price of the stock on September 30, 2022 of \$6.77; d) expected volatility of 53.65%; and e) no expected dividend payments.

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 17. SHARE CAPITAL (continued)

#### (e) Broker Warrants

On January 6, 2020, the Company issued the January 2020 Broker Warrants to purchase up to 6,307 Common Shares at an exercise price of \$129.22 per Common Share at any time prior to January 6, 2023. The fair value at issuance date of \$82,597 for the January 2020 Broker Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 1.60%; b) expected life of one year; c) the price of the stock on the grant date of \$86.75; d) expected volatility of 70%; and e) no expected dividend payments.

On June 16, 2020, the Company issued the June 2020 Compensation Warrants to purchase up to 10,094 Common Shares at an exercise price of \$92.75 per Common Share at any time prior to June 16, 2025. The fair value at issuance date of \$162,467 for the June 2020 Compensation Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 0.32%; b) expected life of two years; c) the price of the stock on the grant date of \$61.75; d) expected volatility of 70%; and e) no expected dividend payments.

On August 12, 2020, the Company issued the August 2020 Compensation Warrants to purchase up to 11,783 Common Shares at an exercise price of \$86.75 per Common Share at any time prior to August 12, 2025. The fair value at issuance date of \$242,989 for the August 2020 Compensation Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 0.32%; b) expected life of two years; c) the price of the stock on the grant date of \$67.50; d) expected volatility of 70%; and e) no expected dividend payments.

On December 8, 2020, the Company issued the December 2020 Compensation Warrants to purchase up to 16,199 Common Shares at an exercise price of \$30.50 per Common Share at any time prior to December 8, 2025. The fair value at issuance date of \$96,114 for the December 2020 Compensation Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 0.33%; b) expected life of two years; c) the price of the stock on the grant date of \$21.50; d) expected volatility of 70%; and e) no expected dividend payments.

On February 12, 2021, the Company issued the February 2021 Compensation Warrants to purchase up to 93,600 Common Shares at an exercise price of \$62.50 per Common Share at any time prior to February 12, 2026. The fair value at issuance date of \$1,898,959 for the February 2021 Compensation Warrants was computed using the Black-Scholes pricing model with the following assumptions: a) average risk-free interest rate of 0.33%; b) expected life of two years; c) the price of the stock on the grant date of \$57.25; d) expected volatility of 70%; and e) no expected dividend payments.

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 18. SEGMENT INFORMATION

The Company's operations are in one business segment: the development, manufacturing and marketing of medical devices. Each of the Company's product lines has similar characteristics, customers, distribution and marketing strategies, and are subject to similar regulatory requirements. Substantially all the Company's long-lived assets are located in Canada. The Company carries on business in Canada, the United States and Europe. The Company earns revenue from sales to customers in the following geographic locations:

	For the three months ended September 30,		For the nine months ended September 30,	
	2022	2021	2022	2021
<b>REVENUE</b>				
Europe	\$ 863,311	\$ 607,920	\$ 2,091,118	\$ 1,612,782
United States	60,000	95,500	195,000	175,500
Rest of the World	-	-	66,000	-
	<b>\$ 923,311</b>	<b>\$ 703,420</b>	<b>\$ 2,352,118</b>	<b>\$ 1,788,282</b>

Sales to the Company's three largest customers accounted for approximately 11%, 10% and 6% of the Company's sales for the nine months ended September 30, 2022. Sales to the Company's three largest customers accounted for approximately 26%, 18%, and 11% of the Company's sales for the nine months ended September 30, 2021.

### 19. EMPLOYEE BENEFITS EXPENSE

	For the three months ended September 30,		For the nine months ended September 30,	
	2022	2021	2022	2021
Salaries and wages	\$ 2,210,875	\$ 1,450,164	\$ 7,016,436	\$ 5,798,890
Pension plan and employment insurance	102,344	82,766	372,165	361,831
Contribution to defined contribution pension plan	61,582	32,432	144,448	107,042
Health benefits	157,460	122,847	444,338	355,582
Cash-based employee expenses	<b>\$ 2,532,261</b>	<b>\$ 1,688,209</b>	<b>\$ 7,977,387</b>	<b>\$ 6,623,345</b>
Employee termination expense	-	(76,640)	-	232,416
Share-based payments	921,600	1,783,675	2,579,930	6,234,751
Total employee expenses	<b>\$ 3,453,861</b>	<b>\$ 3,395,244</b>	<b>\$ 10,557,317</b>	<b>\$ 13,090,512</b>

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

### 20. DEPRECIATION, SHARE-BASED PAYMENTS, EMPLOYEE AND OTHER EXPENSES

	For the three months ended September 30,		For the nine months ended September 30,	
	2022	2021	2022	2021
<b>EXPENSES</b>				
<b>Selling expenses</b>				
Share-based payments	\$ 104,593	\$ 198,168	\$ 272,012	\$ 703,211
Cash-based employee expenses	310,173	161,973	869,650	609,363
Distributor transition fees	-	-	301,075	-
Other expenses	647,688	426,225	1,833,888	944,583
	<b>\$ 1,062,454</b>	<b>\$ 786,366</b>	<b>\$ 3,276,625</b>	<b>\$ 2,257,157</b>
<b>General and administrative expenses</b>				
Depreciation	\$ 12,206	\$ 77,109	\$ 94,770	\$ 228,404
Share-based payments	614,209	1,291,574	1,744,479	4,637,599
Cash-based employee expenses	746,341	494,997	2,657,518	2,149,691
Employee termination expense	-	(76,640)	-	232,416
Write down of fixed assets for obsolescence	-	-	-	593,622
Accretion on collaboration, license and settlement agreements provision	-	12,931	-	63,400
Legal expenses and underwriters fees from financing activities	-	-	148,703	1,630,124
Directors and officers insurance expense	165,986	407,047	1,038,962	844,121
Litigation expenses	149,613	339,328	355,259	820,146
Other expenses	648,519	452,657	2,437,907	2,134,853
	<b>\$ 2,336,874</b>	<b>\$ 2,999,003</b>	<b>\$ 8,477,598</b>	<b>\$ 13,334,376</b>
<b>Product development and clinical trials expenses</b>				
Depreciation	\$ 74,105	\$ 67,979	\$ 215,637	\$ 295,984
Share-based payments	202,798	293,933	563,439	893,941
Cash-based employee expenses	1,475,747	1,031,239	4,450,219	3,864,291
Other expenses	2,291,793	2,084,733	6,426,364	6,785,983
	<b>\$ 4,044,443</b>	<b>\$ 3,477,884</b>	<b>\$ 11,655,659</b>	<b>\$ 11,840,199</b>
<b>TOTAL EXPENSES</b>	<b>\$ 7,443,771</b>	<b>\$ 7,263,253</b>	<b>\$ 23,409,882</b>	<b>\$ 27,431,732</b>
Depreciation per Statements of Cash Flows	\$ 86,311	\$ 145,088	\$ 310,407	\$ 524,388
Share-based payments per Statements of Cash Flows	\$ 921,600	\$ 1,783,675	\$ 2,579,930	\$ 6,234,751
Cash-based employee expenses (see Note 19)	\$ 2,532,261	\$ 1,688,209	\$ 7,977,387	\$ 6,623,345



## NEOVASC INC.

### Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

#### 21. LOSS PER SHARE

Both the basic and diluted loss per share have been calculated using the loss attributable to shareholders of the Company as the numerator. The weighted average number of post-consolidation Common Shares outstanding used for basic loss per share for the for the three and nine months ended September 30, 2022, amounts to 2,744,772 and 2,729,109 (three and nine months ended September 30, 2021: 2,703,418 and 2,456,394).

	For the three months ended		For the nine months ended	
	September 30, 2022	2021	September 30, 2022	2021
Weighted average number of Common Shares	<b>2,744,772</b>	2,703,418	<b>2,729,109</b>	2,456,394
Loss for the period	<b>\$ (8,226,695)</b>	\$ (7,535,597)	<b>\$ (27,363,703)</b>	\$ (18,736,026)
Basic and diluted loss per share	<b>\$ (3.00)</b>	\$ (2.79)	<b>\$ (10.03)</b>	\$ (7.63)

Instruments that could potentially have a dilutive effect on the Company's weighted average shares outstanding include all of the outstanding convertible notes, restricted share units, stock options and warrants. These instruments are currently excluded from the calculation of diluted earnings per share as they are antidilutive for the periods presented.

#### 22. RELATED PARTY TRANSACTIONS

The Company's key management personnel include members of the board of directors and executive officers. The Company provides salaries or cash compensation, and other non-cash benefits to directors and executive officers.

	For the three months ended		For the nine months ended	
	September 30, 2022	2021	September 30, 2022	2021
<b>Short-term employee benefits</b>				
Employee salaries and bonuses	<b>\$ 432,076</b>	\$ 418,560	<b>\$ 1,954,392</b>	\$ 1,553,720
Directors fees	<b>67,500</b>	67,500	<b>202,500</b>	202,500
Social security and medical care costs	<b>20,103</b>	21,077	<b>88,152</b>	71,975
	<b>519,679</b>	507,137	<b>2,245,044</b>	1,828,195
<b>Post-employment benefits</b>				
Contributions to defined contribution pension plan	<b>10,750</b>	10,780	<b>33,603</b>	26,306
<b>Share-based payments</b>	<b>463,656</b>	955,464	<b>1,630,746</b>	2,960,212
<b>Total key management remuneration</b>	<b>\$ 994,085</b>	\$ 1,473,381	<b>\$ 3,909,393</b>	\$ 4,814,713

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 23. CONTINGENT LIABILITIES AND PROVISIONS

#### Litigation

Litigation resulting from-third party claims has been, and may be, costly and time-consuming and could divert the attention of management and key personnel from our business operations. Although we intend to vigorously defend ourselves against any pending claims, and future claims that may occur, we cannot assure that we will succeed in appealing and defending any of these claims and that judgments will not be upheld against us. If we are unsuccessful in our appeal and defense of these claims or unable to settle the claims in a manner satisfactory to us, we may be faced with significant loss of intellectual property rights that could have a material adverse effect on the Company and its financial condition.

#### Claims by CardiAQ in Germany

On June 23, 2014, Edwards Lifesciences CardiAQ LLC ("CardiAQ") filed a complaint against Neovasc in Munich, Germany (the "German Court") requesting that Neovasc assign its right to one of its European patent applications to CardiAQ. After a hearing held on December 14, 2016, the German Court rendered its decision on June 16, 2017, granting co-ownership of the European patent application to CardiAQ but denying their claim for full entitlement. On July 14, 2017, Neovasc filed a notice of appeal against the German Court's decision with the Appeals Court of Munich (the "German Appeals Court"). On July 20, 2017, CardiAQ filed a notice of appeal with the same court. The decision of the German Appeals Court was rendered on March 21, 2019, wherein it amended the decision of the German Court and dismissed the complaint of CardiAQ in full. On March 30, 2020, the German Supreme Court granted CardiAQ leave to appeal the German Appeals Court decision and at a hearing held on August 4, 2020 the German Supreme Court set aside the prior decision of the German Appeals Court and remanded the matter back to the German Appeals Court for a new hearing and decision. The hearing at the German Appeals Court was held on February 25, 2021.

On May 20, 2021, the German Appeals Court upheld the first instance judgment of the German Court of June 16, 2017, in which the court had found that CardiAQ had contributed in part to the invention of the Tiara and awarded to CardiAQ co-entitlement rights to the disputed Tiara European patent application. There are no monetary awards associated with these matters (except for a decision on the statutory costs of the proceedings) and no damages award was recognized. Regarding the statutory costs of the proceedings, each party bears 50% of the costs of the appeal proceedings before the German Appeals Court. Neovasc bears the costs of the 2<sup>nd</sup> appeal proceedings before the German Supreme Court and 50% of the court fees of the first instance proceedings. Neovasc has not appealed this decision to preserve capital and move forward with our new strategic activities. The decision is now final.

#### Other Matters

On August 3, 2018, the Company announced that it had entered into a collaboration and licensing agreement with Penn Medicine and the Gorman Cardiovascular Research Group at the University of Pennsylvania (collectively, "UPenn"), which resolved certain potential claims against the Company that had been previously disclosed. The collaboration and licensing agreement with UPenn contemplates certain fees being paid by Neovasc to UPenn, including fees in installments totaling \$2.65 million over the three years following the agreement's execution. In addition, Neovasc agreed to pay UPenn a royalty of 1.0-1.5% on the annual net sales of the Tiara following the first commercial sale of the Tiara. Also contained in the collaboration and licensing agreement are buy-out clauses that allow Neovasc, or an acquirer of Neovasc or the Tiara assets, to buy out these royalty obligations. As part of the collaboration and licensing agreement, certain potential claims against the Neovasc Defendants were resolved.

On September 7, 2018, Endovalve Inc. and Micro Interventional Devices, Inc. (collectively, "Endovalve") filed a complaint in the United States District Court for the District of New Jersey against the Neovasc Defendants, alleging claims for trade secret misappropriation, breach of contract, and unfair competition. Endovalve alleged that it was a former customer of Neovasc Inc., and that the Neovasc Defendants improperly used trade secrets in the development of Tiara. The complaint sought injunctive relief, money damages, and attorneys' fees. On February 20, 2019, the Company announced that it had entered into a settlement agreement with Endovalve. The settlement agreement with Endovalve contemplates certain fees being paid by Neovasc to Endovalve, including settlement fees in installments totaling \$3 million over the two and a half years following the agreement's execution. In addition, Neovasc agreed to pay Endovalve a royalty of 1.3% on the annual net sales of the Tiara following the first commercial sale of the Tiara. Also contained in the settlement agreement are buy-out clauses that allow Neovasc, or an acquirer of Neovasc or the Tiara assets, to buy out these royalty obligations. As part of the settlement agreement, the claims against the Neovasc defendants were dismissed with prejudice.

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 23. CONTINGENT LIABILITIES AND PROVISIONS (continued)

#### Other Matters (continued)

When the Company assesses that it is more likely that a present obligation exists at the end of the reporting period and that the possibility of an outflow of economic resources embodying economic benefits is probable, a provision is recognized and contingent liability disclosure is required. The Company has not accrued for any future royalty payments in the settlement agreement with UPenn or Endovalve as the amounts are undeterminable at this time.

#### Shareholder Litigation

On November 5, 2020, a putative shareholder class action lawsuit was filed in the United States District Court for the Southern District of New York against Neovasc, Fred Colen, Neovasc's CEO, and Christopher Clark, Neovasc's CFO: Gonzalez v. Neovasc Inc., et al., Case No. 7:20-cv-09313 (S.D.N.Y.) (the "Gonzalez Action"). The complaint in the Gonzalez Action purported to bring suit on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Neovasc securities between November 1, 2019 and October 27, 2020, inclusive. On November 25, 2020, a second putative shareholder class action lawsuit was filed in the United States District Court for the Southern District of New York against Neovasc and Messrs. Colen and Clark: Siple v. Neovasc Inc., et al., Case No. 1:20-cv-09948 (S.D.N.Y.) (the "Siple Action"). The complaint in the Siple Action purported to bring suit on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Neovasc securities between October 10, 2018 and October 27, 2020, inclusive.

The complaints in both the Gonzalez Action and the Siple Action contained similar allegations that the defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Neovasc's business, operations, and prospects. Specifically, the complaints' allegations relate to the premarket approval process with the U.S. Food and Drug Administration for Neovasc's Reducer medical device for the treatment of refractory angina. Both complaints asserted the same two causes of action: (i) a violation of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 promulgated thereunder against all defendants; and (ii) a violation of Section 20(a) of the Exchange Act against Messrs. Colen and Clark.

On January 26, 2021, the court issued an order consolidating the Gonzalez Action and the Siple Action under a new case style: In re Neovasc Inc. Securities Litigation, Case No. 7:20-cv-09313 (S.D.N.Y.) (the "Consolidated Action"). The order also appointed Pratap Golla as the lead plaintiff (the "Lead Plaintiff") and the law firms of Pomerantz LLP and Holzer & Holzer LLC as Co-Lead Counsel for the class in the Consolidated Action. The order further directed the Lead Plaintiff to file a Consolidated Amended Complaint in the Consolidated Action. On March 19, 2021, the Lead Plaintiff filed a Consolidated Amended Complaint.

The Consolidated Amended Complaint named Neovasc, Messrs. Colen and Clark, Bill Little, Neovasc's COO, and Shmuel Banai, Neovasc's Medical Director, as defendants (the "Defendants"). The Consolidated Amended Complaint purported to bring suit on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Neovasc securities between October 10, 2018 and January 15, 2021, inclusive. The Consolidated Amended Complaint contained allegations similar to the complaints in the Gonzalez Action and the Siple Action and asserted the same two causes of action: (i) a violation of Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder against all defendants; and (ii) a violation of Section 20(a) of the Exchange Act against Messrs. Colen, Clark, Little, and Banai.

Defendants' motion to dismiss the Consolidated Amended Complaint was served on June 14, 2021. On February 1, 2022, after the conclusion of oral argument on Defendants' motion to dismiss, the Consolidated Amended Complaint was dismissed in its entirety with prejudice and without leave to amend. On February 22, 2022, the Lead Plaintiff filed an appeal to the United States Court of Appeals for the Second Circuit (the "Court of Appeals"). On May 13, 2022, The Lead Plaintiff filed their initial appellate brief. On August 10, 2022, the Defendants filed their response appellate brief. On August 31, 2022, the Lead Plaintiff filed their reply brief. The Company anticipates that oral arguments will be heard sometime in early 2023.

# NEOVASC INC.

## Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2022 and 2021

(Expressed in U.S. dollars)

---

### 24. SUBSEQUENT EVENTS

The Company has evaluated events subsequent to September 30, 2022 through the date of this filing to assess the need for potential recognition or disclosure. Based upon this evaluation, it was determined that no subsequent events occurred that require recognition or disclosure in the Consolidated Financial Statements.

### 25. AUTHORIZATION OF FINANCIAL STATEMENTS

The unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2022 and 2021 (including comparatives) were approved by the audit committee on behalf of the board of directors on November 8, 2022.

*/s/ Chris Clark*

---

Chris Clark, Chief Financial Officer

*/s/ Paul Geyer*

---

Paul Geyer, Director